Jilun Zhang

Testing insulin‐like growth factor messenger RNA–binding protein 3 as a surrogate immunohistochemical marker for indeterminate thyroid nodules with THADA fusion in both cytologic and surgical specimens

Di Ai, Youjie Zhang, Kartik Viswanathan, Jilun Zhang et autres

BACKGROUND: Thyroid adenoma-associated (THADA) gene fusions are recurrent alterations in thyroid nodules that lead to the overexpression of insulin-like growth factor messenger RNA-binding protein 3 (IMP3). Although IMP3 immunohistochemistry has been studied in thyroid tumors, its utility for detecting THADA fusion-positive thyroid …

us (code pays fourni par la source)

Process optimization for synthesizing α-Al2O3 with tailored morphology and dispersibility by interpretable incremental machine learning

Jilun Zhang, Huaqiang Zhu, Nian Zhou, Xiangdong Su

Abstract PS4-09: Spatial Omics Analysis Uncovers Microenvironmental Remodeling and Immune Dynamics in T-DXd Resistant Metastatic Breast Cancer

Glori Das, Matthew C. Vasquez, Jeffrey Zhang, Ji Hoon Lee et autres

Abstract Trastuzumab deruxtecan (T-DXd) is the standard of care for HER2+ or HER2 low metastatic breast cancer (mBC). However, approximately 20% of patients exhibit resistance to T-DXd therapy. As the development of more antibody-drug conjugate (ADC) therapies progresses, understanding ADC resistance mechanisms …

Proposing New Criteria for Classification of Benign Fibroepithelial Lesions Based on Clinicopathologic Evaluations of 507 Cases with Clinical Outcome

Thi Truc Anh Nguyen, Jilun Zhang, Jabed Iqbal, Syed Salahuddin Ahmed et autres

us, sg, cn (code pays fourni par la source)

HAI-score, an objective HER2 artificial intelligence method for accurate H-score estimation from IHC-stained breast cancer samples.

Sahar Almahfouz Nasser, Jilun Zhang, Tilak Bahadur Pathak, Geoff V. Smith et autres

1116 Background: Accurate HER2 assessment is essential for breast cancer (BC) treatment, as it directs targeted therapy decisions and predicts patient prognosis. While immunohistochemistry (IHC) is widely used, its manual scoring is susceptible to inter-observer variability. RNAscope, an RNA in situ hybridization …

us (code pays fourni par la source)

Brain-like path planning algorithm based on spiking neural network

Jilun Zhang, Ying Liu

This paper proposes a brain-like path planning algorithm based on spiking neural networks (SNNs), which draws on the neural phenomena of hippocampal place cells and related navigation behaviors in neuroscience. By simulating the pulse sequence propagation characteristics of spiking neurons, the algorithm …

cn (code pays fourni par la source)

207 Clinicopathologic Evaluations of 500 Cellular Fibroadenoma, Benign and Borderline Phyllodes Tumors Indicate the Current Classification May Not Have Clinical Implications

Thanh Thi Nguyen, Jilun Zhang, Jabed Iqbal, Syed Udoy Ahmed et autres

us, sg, cn (code pays fourni par la source)

Process Optimization for Synthesizing Α-Al2o3 with Tailored Morphology and Dispersibility by Interpretable Incremental Machine Learning

Jilun Zhang, Huaqiang Zhu, Nian Zhou, Xiangdong Su

cn (code pays fourni par la source)

WITHDRAWN: Neuroprotective effects of biogenic silver nanoparticles in Parkinson's disease: In vitro and in vivo study

Siren Zhao, Jilun Zhang, Jianbin Zhang

The study aimed to develop immunomodulatory silver nanoparticles (CHT-PCT/AgNPs) using a green chemistry approach with Umbilicaria esculenta (U.E.) extract to protect neurons from Parkinson's disease. The synthesized CHT-PCT/AgNPs measured 88.2 ± 33.7 nm in size, with a zeta potential of approximately 24.5 …

cn (code pays fourni par la source)

Validation Study of the Newly Proposed Refined Diagnostic Criteria for Malignant Phyllodes Tumor With 136 Borderline and Malignant Phyllodes Tumor Cases

Xiaoxian Li, Thi Truc Anh Nguyen, Jilun Zhang, Anupma Nayak et autres

The World Health Organization (WHO) diagnostic criteria for malignant phyllodes tumor (MPT) may miss a significant number of MPTs with metastatic potential. New refined diagnostic criteria (Refined Criteria) for MPT were recently proposed. The aim of this study is to validate the …

us, cn (code pays fourni par la source)

Abstract PO3-13-03: RNAScope: a practical approach and promising alternative to immunohistochemistry to quantify HER2 expression in breast cancer

Xiaoxian Li, Ji-Hoon Lee, Yuan Gao, Jilun Zhang et autres

Abstract T-DXd has been approved by the FDA to treat patients with metastatic HER2-low and -positive breast cancer. The utility of current HER2 immunohistochemistry (IHC) assays in evaluating HER2-low tumors is not clear. A simple and objective method to evaluate HER2 expression …

us (code pays fourni par la source)

Abstract PO1-29-04: Spatial tumor microenvironment profiling identifies immune features that correlate with response to T-DXd treatment in patients with metastatic breast cancer

Hong Yun Zhao, Matthew C. Vasquez, Jeffrey Zhang, Glori Das et autres

Abstract Objective: It is unclear which patients with metastatic breast cancer respond to the new antibody drug conjugate T-DXd treatment. Methods: We profiled 22 pre-T-DXd treatment metastatic tissue samples from patients using Nanostring GeoMX digital spatial profiler of tumor infiltrating immune cells …

us (code pays fourni par la source)